Previous 10 | Next 10 |
2023-12-04 09:50:28 ET More on SPDR S&P 500 ETF Trust: Bears Refuse To Acknowledge New All-Time Highs In 2024 SPY Is A Buy According To The 200-Day Simple Moving Average When Do You Take Profits? Top 10 trades for 2024 - BofA S&P 500 hits new ...
IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy® and IDE397 Combination in MTAP-Deletion Bladder Cancer PR Newswire Entered into Clinical Study Collaboration and Supply Agreement with Gilead to evaluate IDE397, IDEAYA's MAT2A inhibi...
IDEAYA Announces Agenda for Investor R&D Day Webcast on December 4, 2023 IDEAYA Announces Agenda for Investor R&D Day Webcast on December 4, 2023 PR Newswire SOUTH SAN FRANCISCO, Calif. , Dec. 3, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NAS...
2023-11-17 18:40:33 ET Summary Delcath's Hepzato Kit is the only liver directed FDA approved treatment for mUM, a rare form of cancer. It will launch in the US in January. The treatment had a 36.3% objective response rate, outperforming the best available alternative treatment by ...
2023-11-15 07:00:00 ET Summary Biotech stocks, long burdened by concerns over rising yields, are poised for improvement as the 10-year yield may have peaked, signaling a potential upswing in the industry's fortunes. The recent uptrend in the 10-year yield, peaking around 5% in Oct...
IDEAYA Biosciences Inc. (IDYA) is expected to report $-0.47 for Q3 2023
2023-11-07 06:28:59 ET More on IDEAYA Biosciences IDEAYA's Triple Threat: Melanoma, Money, And Momentum Ideaya Biosciences: Eye Cancer Therapy Drives Gains - More Upside Ahead IDEAYA Biosciences down 9%, prices $125M offering IDEAYA announces proposed public ...
IDEAYA Biosciences, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update PR Newswire Strong balance sheet of $511.1 million of cash, cash equivalents and marketable securities as of September 30, 2023 , supplemented by $134.7 million estim...
IDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Jefferies London Healthcare Conference IDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Jefferies London Healthcare Conference PR Newswire SOUTH SAN FRANCISCO...
2023-10-25 11:55:27 ET Ideaya Biosciences (NASDAQ: IDYA) stock is falling in Wednesday's trading. The company's share price was down 8.1% as of 11 a.m. ET, according to data from S&P Global Market Intelligence . Ideaya Biosciences published a press release after the mark...
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NYSE Market:
IDEAYA Biosciences Inc. Website:
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer PR Newswire First-Patient-In (FPI) for Phase 1 combination treatment with IDE397, IDEAYA's MAT2A inhibitor, and Trodelvy ...
IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors PR Newswire Targeting IDE397 Phase 2 monotherapy expansion dose clinical data update in over ~15 evaluable MTAP lung an...
IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study PR Newswire 75% eye preservation rate (9 of 12 enucleation patients) ~67% (8 of 12 enucleation patients...